Drug discovery of sclerostin inhibitors

Drug discovery of sclerostin inhibitors

Sclerostin, a protein secreted from osteocytes, negatively regulates the WNT signaling pathway by binding to the LRP5/6 co-receptors and further inhibits bone formation and promotes bone resorption. Sclerostin contributes to musculoskeletal system-related diseases, making it a promising therapeutic...

Full description

Bibliographic Details
Main Authors: Sifan Yu, Dijie Li, Ning Zhang, Shuaijian Ni, Meiheng Sun, Luyao Wang, Huan Xiao, Dingdong Liu, Jin Liu, Yuanyuan Yu, Zongkang Zhang, Samuel Tin Yui Yeung, Shu Zhang, Aiping Lu, Zhenlin Zhang, Baoting Zhang, Ge Zhang
Format: Article
Language:English
Published: Elsevier 2022-05-01
Series:Acta Pharmaceutica Sinica B
Subjects:
Sclerostin
WNT signalling pathway
Sclerostin inhibitors
Antibody
Bone diseases
Aptamer
Online Access:http://www.sciencedirect.com/science/article/pii/S2211383522000259

Internet

http://www.sciencedirect.com/science/article/pii/S2211383522000259

Similar Items